Optimizing ovulation induction in women with polycystic ovary syndrome

Current Opinion in Obstetrics and Gynecology

Volumn 14, Issue 3, 2002, Pages 245-254

  Seli, Emre ^a   Duleba, Antoni J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; ANTIESTROGEN; CLOMIFENE CITRATE; FOLLITROPIN; GONADOTROPIN DERIVATIVE; HUMAN MENOPAUSAL GONADOTROPIN; INSULIN; LUTEINIZING HORMONE; METFORMIN; TROGLITAZONE;

ANOVULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; DOSE RESPONSE; EXERCISE; FEMALE; FEMALE INFERTILITY; HORMONAL THERAPY; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INFERTILITY THERAPY; INSULIN RESISTANCE; INSULIN SENSITIVITY; KINESIOTHERAPY; LAPAROSCOPIC SURGERY; MULTIPLE PREGNANCY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; OVULATION; OVULATION INDUCTION; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

CLINICAL TRIALS; CLOMIPHENE; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; METFORMIN; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY;

EID: 0036266240     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200206000-00002     Document Type: Review

References (61)

1. Amenorrhea associated with bilateral polycystic ovaries
2. Medical implications of ultrasonically detected polycystic ovaries
3. Polycystic ovaries: A common finding in normal women
4. How common are polycystic ovaries in normal women and what is their significance for the fertility of the population
5. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism
6. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study
7. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain
8. Polycystic ovary syndrome: A changing perspective
9. Polycystic ovary syndrome: The spectrum of the disorder in 1741 patients
10. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome
11. Heterogeneity of the polycystic ovary syndrome: Clinical, endocrine and ultrasound features in 556 patients
12. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women
13. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone
14. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women
15. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment
16. Intensity and amount of physical activity in relation to insurin sensitivity: The Insulin Resistance Atherosclerosis Study
17. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
18. Decreases in ovarian cytochrome p450c1 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome
19. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome
20. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome
21. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome
22. The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome
23. Metformin-induced resumption of normal menses in 39 of 43 (91%) previousry amenorrheic women with the polycystic ovary syndrome
24. Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhea
25. Metformin therapy improves hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome
26. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in porycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
27. Hyperinsulinemia in polycystic ovarian syndrome correlates with increased cardiovascular risk independent of obesity
28. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian p450c17alpha activity and serum androgens
29. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women
30. Can metformin reduce insulin resistance in polycystic ovary syndrome?
31. Effects of Metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome
32. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: A randomized, double-blinded placebo-controlled trial
33. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: A pilot study
34. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
35. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone
36. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome
37. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of insulin-like growth factors
38. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
39. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double-blind, placebo-controlled trial
40. Surgically induced ovulation in the polycystic ovary syndrome: Wedge resection revisited in the age of laparoscopy
41. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope
42. Success of laparoscopic ovarian wedge resection is related to obesity, lipid profile and insulin levels
43. Minilaparoscopic ovarian drilling under local anesthesia in patients with polycystic ovary syndrome
44. Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels
45. Effects of laparoscopic ovarian drilling on serum vascular endothelial growth factor and on insulin responses to the oral glucose tolerance test in women with polycystic ovary syndrome
46. Effects of laparoscopic ovarian drilling on adrenals steroids in polycystic ovarian syndrome patients with and without hyperinsulinemia
47. Laparoscopic ovarian electrocautery in patients with polycystic ovarian disease resistant to clomiphene citrate
48. Evaluation of adhesion formation after laparoscopic treatment of polycystic ovarian disease
49. The effect of short-interval laparoscopic lysis of adhesions on pregnancy rates following Nd-YAG laser photocoagulation of polycystic ovaries
50. Ovarian electrocautery versus human menopausal gonadotrophins and pure follicle stimulating hormone therapy in the treatment of patients with polycystic ovarian disease
51. Laparoscopic "diathermy" or laser for ovulation induction in anovulatory polycystic ovary syndrome
52. Ovulation and pregnancy rates with clomiphene citrate
53. Clomiphene citrate for unexplained subfertility in women
54. Ovulation induction with urinary follicle stimulating hormone vs human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome
55. Recombinant follicle stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant, normogonadotropic, chronic anovulation: A prospective, multicenter, assessor-blind, randomized clinical trial
56. Low-dose FSH stimulation in polycystic ovary syndrome: Comparison of 3 FSH preparations
57. The use of human gonadotropins for the induction of ovulation in women polycystic ovary disease
58. Ovulation induction and polycystic ovary syndrome
59. A comparative, randomized study of low-dose human menopausal gonadotropin and follicle stimulating hormone in women with polycystic ovarian syndrome
60. Purified follicle-stimulating hormone in polycystic ovary syndrome: Slow administration is safer and more effective
61. Induction of ovulation with low dose gonadotropins in polycystic ovary syndrome: An analysis of 109 pregnancies in 225 women